Board of Directors

Dr. William Garner, MD

Chairman of the Board of Director

Dr. Garner is the founder of EGB Advisors PR LLC, a pharmaceutical commercialization boutique, where he has focused on advancing technologies and companies to significant value inflection points leading to monetization of

assets via licensing, M&A or IPO transactions.

Dr. Garner has extensive director-level and executive management experience, including his current role as Chairman & Founder of Update Pharma and as a Director at IGXBio; previously serving as CEO of Invion Limited (ASX:IVX), a clinical-stage anti-inflammatory drug development company that resulted from the merger of a private company he founded; and as a co-founder and Director of Del Mar Pharmaceuticals (OCTQX:DMPID). He also brings extensive medical affairs experience from his tenure at Hoffmann LaRoche’s oncology division.

Dr. Garner holds a Master of Public Health degree from Harvard and earned his M.D. from New York Medical College; performing residency training in Anatomic Pathology at Columbia-Presbyterian Hospital.
Learn More

Martin Bott, MIBS

Director

Mr. Bott brings over 28 years’ experience in senior financial and executive leadership to InMed’s Board of Directors. He currently serves as V.P. of Corporate Finance and Investment Banking at Eli Lilly & Company. Mr. Bott joined

Lilly in 1988 and has held roles of increasing responsibility at their headquarters in Indianapolis as well as affiliates in Switzerland, Germany, and the UK. Prior to his current assignment, Mr. Bott was the CFO for both the Diabetes Business and the Global Manufacturing and Quality organizations. He has been a member of the Lilly CFO Staff since December 2002.

Mr. Bott has a Master’s in International Business Studies (University of South Carolina, 1988) and a Bachelor’s of Business / Marketing (Cologne, Germany, 1985).
Learn More

Adam Cutler

Director

Mr. Cutler brings more than 20 years of experience in the global healthcare industry where he has held senior leadership positions in equity research, corporate finance, business development and management consulting. Mr.

Cutler has earned a reputation as a top-ranked biotechnology sell-side analyst, executive, and advisor, with extensive knowledge of biotech product development, the global healthcare environment, and the US financial community.

Mr. Cutler currently serves as Chief Financial Officer of Molecular Templates and previously served as Senior Vice President of Corporate Affairs at Arbutus Biopharma. Before joining Arbutus, Mr. Cutler served as Managing Director at The Trout Group LLC and Trout Capital LLC, where he successfully executed financings and advised a wide range of life science companies on investor relations, business development, and capital raising strategy. Mr. Cutler spent almost 12 years as a sell-side equity research analyst with Credit Suisse, Canaccord Genuity, JMP Securities, and Bank of America Securities. Mr. Cutler began his career in healthcare management consulting with Ernst & Young and then The Frankel Group.

Mr. Cutler holds a BA in Economics from Brandeis University.
Learn More

Andrew Hull, BA

Director

Mr. Hull has over 30 years’ experience in various commercial and business development roles with leading pharmaceutical and biotech companies. He most recently served as Vice President of Global Alliances for Takeda

Pharmaceuticals where he was responsible for maximizing the success of Takeda’s growing number (40+) of commercial and R&D partnerships with many of the industry’s leading pharmaceutical and biotech companies. In previous roles, he led marketing and commercial development of Takeda’s US portfolio of over $3B including diabetes, neuroscience, GI and cardiovascular therapies. Additionally, he held positions of increasing responsibility at Immunex and Abbott Labs.

Mr. Hull received a bachelor’s degree in biology from Kenyon College in 1985. He has served as a member of the Board of Directors of the Illinois Biotechnology Industry Organization and as a member of the Kenyon College Board of Trustees.
Learn More

Eric A. Adams, MIBS

Chief Executive Officer & President

Eric A. Adams was appointed Chief Executive Officer, President and Director of InMed Pharmaceuticals, Inc. in June 2016. During his tenure at InMed, he has reconstituted the Board of Directors and the Executive management

team and has raised more than $35M in capital to fund operations. Mr. Adams is a seasoned biopharmaceutical executive with over 25 years’ experience in establishing corporate entities, capital formation, global market development, mergers & acquisitions, licensing and corporate governance.

Mr. Adams previously served as CEO at enGene Inc., where he oversaw its transformation from a nascent start-up into a venture capital-backed leader in gene therapy. Prior to enGene, Mr. Adams held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissues Science Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL), and Fresenius AG (Germany). As the previous Chairman of BIOTECanada’s Emerging Company Advisory Board, and for his extensive generosity in mentoring biotech entrepreneurs, Mr. Adams is well respected within the Canadian biotech industry as a strategic advisor to a number of early-stage biotech companies.

He is a dual citizen of Canada and the United States, and holds a Masters of International Business from the University of South Carolina and a Bachelor’s Degree in Chemistry from the University of Southern Indiana.
Learn More

Overview

Management

Scientific Advisory Board

Stay up to Date​

Subscribe to all of our investor information, including news, events, presentations and more